Request Appointment
520 East 70th StreetStarr Pavilion, 3rd FloorNew York, NY 10021
Overview of Dr. Beltran
Dr. Himisha Beltran is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital, Dana-Farber Cancer Institute, and Brigham and Women's Hospital. She received her medical degree from New York Medical College and has been in practice 18 years. She is one of 451 doctors at Dana-Farber Cancer Institute and one of 361 doctors at Brigham and Women's Hospital who specialize in Oncology. She has more than 100 publications and over 500 citings.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2008 - 2011
University of Pennsylvania Health SystemResidency, Internal Medicine, 2004 - 2007
New York Medical CollegeClass of 2004
Certifications & Licensure
MA State Medical License 2019 - 2025
NH State Medical License 2024 - 2024
NY State Medical License 2008 - 2019
PA State Medical License 2007 - 2008
American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001) Start of enrollment: 2020 Dec 14
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- State of the Art: Personalizing Treatment for Patients With Metastatic Castration-Resistant Prostate Cancer.Wassim Abida, Himisha Beltran, Ruben Raychaudhuri
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 2025-06-01 - Targeting the tumour cell surface in advanced prostate cancer.Cristina Boixareu, Tarek Taha, Varadha Balaji Venkadakrishnan, Johann de Bono, Himisha Beltran
Nature Reviews. Urology. 2025-04-01 - Clinical Implementation of Minimal Residual Disease Testing in Genitourinary Cancers: Bridging Promise and Practice.Rana R McKay, Joshua Lang, Himisha Beltran
European Urology. 2025-04-01
Journal Articles
- Activity of Platinum-Based Chemotherapy in Patients with Advanced Prostate Cancer with and Without DNA Repair Gene AberrationsHimisha Beltran, Che-Kai Tsao, Tomasz M Beer, JAMA Network Open
Press Mentions
The Challenge of Finding New Tools to Fight Prostate CancerSeptember 9th, 2021- BET Inhibitors Show Promise in Overcoming Lineage Plasticity, a Newly Recognized Form of Resistance to Prostate Cancer DrugsJune 18th, 2021
- Dana-Farber Cancer Institute, a Pioneer in Cancer Care and Research, Joins Caris' Precision Oncology AllianceFebruary 16th, 2021
- Join now to see all
Grant Support
- "DNMT and TET1 reprogramming as a targetable mechanism of resistance in advanced prostate cancer"WEILL MEDICAL COLL OF CORNELL UNIV2023–2028
- DF/HCC Prostate SPOREDANA-FARBER CANCER INST2023–2028
- DF/HCC Prostate SPOREDANA-FARBER CANCER INST2023–2028
- DF/HCC Prostate SPOREDANA-FARBER CANCER INST2023–2028
- DF/HCC Prostate SPOREDANA-FARBER CANCER INST2023–2028
- DF/HCC Prostate SPOREDANA-FARBER CANCER INST2023–2028
- Molecular mechanisms underlying lineage plasticity in prostate cancerDANA-FARBER CANCER INST2020–2025
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
